These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30216418)

  • 21. Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients.
    Wang L; Wu Z; Tian K; Wang K; Li D; Ma J; Jia G; Zhang L; Zhang J
    J Neurosurg; 2017 Dec; 127(6):1257-1267. PubMed ID: 28059654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
    Grignani G; Palmerini E; Ferraresi V; D'Ambrosio L; Bertulli R; Asaftei SD; Tamburini A; Pignochino Y; Sangiolo D; Marchesi E; Capozzi F; Biagini R; Gambarotti M; Fagioli F; Casali PG; Picci P; Ferrari S; Aglietta M;
    Lancet Oncol; 2015 Jan; 16(1):98-107. PubMed ID: 25498219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update.
    Bajetta E; Catena L; Pusceddu S; Spada F; Iannacone C; Sarno I; Di Menna G; Dottorini L; Marte AM
    Neuroendocrinology; 2018; 106(4):307-311. PubMed ID: 28743120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clival chordoma: a single-centre outcome analysis.
    Jägersberg M; El Rahal A; Dammann P; Merkler D; Weber DC; Schaller K
    Acta Neurochir (Wien); 2017 Oct; 159(10):1815-1823. PubMed ID: 28478512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chordoma: long-term follow-up after radical photon irradiation.
    Catton C; O'Sullivan B; Bell R; Laperriere N; Cummings B; Fornasier V; Wunder J
    Radiother Oncol; 1996 Oct; 41(1):67-72. PubMed ID: 8961370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
    Zucali PA; De Pas T; Palmieri G; Favaretto A; Chella A; Tiseo M; Caruso M; Simonelli M; Perrino M; De Vincenzo F; Toffalorio F; Damiano V; Pasello G; Garbella E; Ali M; Conforti F; Ottaviano M; Cioffi A; De Placido S; Giordano L; Bertossi M; Destro A; Di Tommaso L; Santoro A
    J Clin Oncol; 2018 Feb; 36(4):342-349. PubMed ID: 29240542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Yoo C; Lee J; Rha SY; Park KH; Kim TM; Kim YJ; Lee HJ; Lee KH; Ahn JH
    Invest New Drugs; 2013 Dec; 31(6):1602-8. PubMed ID: 24037083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
    Bompas E; Le Cesne A; Tresch-Bruneel E; Lebellec L; Laurence V; Collard O; Saada-Bouzid E; Isambert N; Blay JY; Amela EY; Salas S; Chevreau C; Bertucci F; Italiano A; Clisant S; Penel N
    Ann Oncol; 2015 Oct; 26(10):2168-73. PubMed ID: 26202596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.
    Stacchiotti S; Verderio P; Messina A; Morosi C; Collini P; Llombart-Bosch A; Martin J; Comandone A; Cruz J; Ferraro A; Grignani G; Pizzamiglio S; Quagliuolo V; Picci P; Frustaci S; Dei Tos AP; Casali PG; Gronchi A
    Cancer; 2012 Dec; 118(23):5857-66. PubMed ID: 22605504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
    Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
    Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect comparisons among treatment measures on progression-free survival in patients with skull base chordomas: a retrospective study of 234 post-surgical cases.
    Wang L; Tian K; Ma J; Wang K; Jia G; Wu Z; Zhang L; Zhang J
    Acta Neurochir (Wien); 2017 Oct; 159(10):1803-1813. PubMed ID: 28699066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
    Kasper B; Gruenwald V; Reichardt P; Bauer S; Rauch G; Limprecht R; Sommer M; Dimitrakopoulou-Strauss A; Pilz L; Haller F; Hohenberger P
    Eur J Cancer; 2017 May; 76():60-67. PubMed ID: 28282612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
    Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
    Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
    Mirza AS; Lancet JE; Sweet K; Padron E; Pinilla-Ibarz J; Nardelli L; Cubitt C; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):902-907. PubMed ID: 29030092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Everolimus Plus Letrozole for Treatment of Patients With HR
    Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
    Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
    Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.